Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11388536 | 0.98 | CYP2C19 (0.35) | CYP2C19FFAR3 | |
| SCHEMBL28979974 | 0.98 | FFAR3 (0.36) | CYP2C19FFAR3AKR1C1 | |
| SCHEMBL15114668 | 0.87 | — | — | |
| SCHEMBL306724 | 0.82 | — | — | |
| SCHEMBL13736831 | 0.80 | CYP2C19 (0.39) | CYP2C19FFAR3ALDH1A1SMN1; SMN2AKR1C1 | |
| Methyl Alcohol SCHEMBL16395828 | 0.79 | CYP2C19 (0.42) | CYP2C19FFAR3ALDH1A1SMN1; SMN2AKR1C1 | |
| Cyclohexane SCHEMBL1430293 | 0.79 | CYP2C19 (0.42) | CYP2C19FFAR3ALDH1A1SMN1; SMN2AKR1C1 | |
| Methyl Alcohol SCHEMBL2126883 | 0.79 | CYP2C19 (0.42) | CYP2C19FFAR3ALDH1A1SMN1; SMN2AKR1C1 | |
| SCHEMBL11408757 | 0.79 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2LMNABLM | |
| SCHEMBL11214274 | 0.79 | CYP2C19 (0.46) | CYP2C19FFAR3ALDH1A1SMN1; SMN2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115724797-A | Fluoroalkylated 3, 4-polysubstituted dihydroisoquinoline skeleton novel compound and preparation method thereof | 兰州大学 | 2023-03-03 | — | — | CN | disclosed |
| EP-2253328-A1 | Cycloalkyl inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-2253328-A1 | Cycloalkyl inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050234106-A1 | Cycloalkyl inhibitors of potassium channel function | LLOYD JOHN | 2005-10-20 | — | — | US | disclosed |
| EP-1507504-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | Bristol-Myers Squibb Company (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20040072880-A1 | Cycloalkyl inhibitors of potassium channel function | ICAGEN, INC. | 2004-04-15 | — | — | US | disclosed |
| WO-2003063797-A2 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-07 | — | — | WO | disclosed |
| US-4283420-A | ANTICONVULSANTS, ANTIANAPHYLACTIC AGENTS, ANTIPSYCHOTIC AGENTS | LABAZ (FR) | 1981-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234106-A1 | Cycloalkyl inhibitors of potassium channel function | KCNJ2, KCNN3, KCNQ5 | CYP2C19 4003/4885FFAR3 1005/4885ALDH1A1 4075/4885 |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNN3, KCNQ5 | CYP2C19 4003/4885FFAR3 1005/4885ALDH1A1 4075/4885 |
| US-20040072880-A1 | Cycloalkyl inhibitors of potassium channel function | KCNN1, KCNN2, KCNH2 | CYP2C19 4043/4885FFAR3 2114/4885ALDH1A1 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.